GeneDx Holdings Corp（WGS）資訊與事件WGSGeneDx Holdings Corp

GeneDx Launches Long-Read Whole Genome Sequencing

The company states: "GeneDx announced plans to enhance its genome testing portfolio with long-read whole genome sequencing. Long-read sequencing analyzes longer stretches of DNA to identify complex genetic variation, including certain structural variants and repeat expansions that can go undetected by traditional short-read sequencing. With years of published research1 and collaborations with leading technology partners, GeneDx is uniquely positioned to bring long-read sequencing into clinical practice, combining advanced sequencing of genomic data, rich phenotypic data, and deep clinical expertise to deliver meaningful answers for patients."

GeneDx Launches Long-Read Whole Genome Sequencing Service

GeneDx announced plans to enhance its genome testing portfolio with long-read whole genome sequencing, lrWGS. Leveraging insights from GeneDx Infinity and decades of clinical interpretation, GeneDx will identify where long-read sequencing can deliver diagnostic value and offer lrWGS upfront for eligible patients. This targeted, phenotype-driven approach aims to reduce sequential testing, close diagnostic gaps and accelerate diagnosis.

GeneDx Announces New Advances in Newborn Genomic Screening

GeneDx announced new findings to be presented at the International Consortium on Newborn Sequencing, ICoNS, October 7-8 in Boston, demonstrating progress toward making genomic newborn screening a scalable and accessible part of proactive healthcare. New findings from GUARDIAN, which has now enrolled 30,000 newborns, demonstrate the feasibility and clinical impact of gNBS: 72.3% of families approached chose to enroll, demonstrating strong uptake of gNBS. 76% of participating newborns represent non-European genetic ancestry. Genomic screening identified conditions missed by standard approaches due to atypical presentations or the absence of biochemical biomarkers, including hearing loss in infants who passed their initial newborn hearing screen. gNBS can identify serious, treatable conditions lacking traditional newborn screening biomarkers, including Long QT syndrome, a cardiac conduction disorder associated with life-threatening arrhythmias. Among infants diagnosed with Long QT syndrome through GUARDIAN, eight have initiated beta-blocker therapy and all are avoiding medications known to prolong QT intervals. Cascade testing also identified risk among family members, leading six parents and one older sibling to begin preventive beta-blocker treatment.